Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET GlobeNewswire - Fri Apr 24, 5:50AM CDT

PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results...

ANIP : 82.69 (+2.86%)
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity GlobeNewswire - Mon Apr 20, 5:50AM CDT

PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets...

ANIP : 82.69 (+2.86%)
EVER
1 Cash-Producing Stock with Promising Prospects and 2 Facing Challenges StockStory - Mon Apr 13, 11:31PM CDT

1 Cash-Producing Stock with Promising Prospects and 2 Facing Challenges

ANIP : 82.69 (+2.86%)
SNX : 226.26 (-0.85%)
EVER : 14.45 (-0.28%)
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules GlobeNewswire - Mon Apr 13, 5:50AM CDT

PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg...

ANIP : 82.69 (+2.86%)
ANIP
1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down StockStory - Sun Apr 12, 11:34PM CDT

1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down

EBC : 19.94 (-1.58%)
NOG : 26.96 (+1.66%)
ANIP : 82.69 (+2.86%)
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet GlobeNewswire - Wed Apr 8, 5:50AM CDT

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration...

ANIP : 82.69 (+2.86%)
AORT
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know StockStory - Tue Apr 7, 12:45PM CDT

Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know

PRVA : 24.31 (-2.17%)
ANIP : 82.69 (+2.86%)
AORT : 35.54 (-1.85%)
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology GlobeNewswire - Tue Apr 7, 5:50AM CDT

PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving...

ANIP : 82.69 (+2.86%)
SMPL
3 Russell 2000 Stocks We Steer Clear Of StockStory - Sun Mar 29, 11:31PM CDT

3 Russell 2000 Stocks We Steer Clear Of

SMPL : 12.89 (-2.57%)
OBK : 46.17 (-2.45%)
ANIP : 82.69 (+2.86%)
ANIP
3 Reasons ANIP is Risky and 1 Stock to Buy Instead StockStory - Mon Mar 23, 11:04PM CDT

3 Reasons ANIP is Risky and 1 Stock to Buy Instead

ANIP : 82.69 (+2.86%)

Barchart Exclusives

Super Micro: A Windfall or a Legal Snare? Barchart - 3 minutes ago
Super Micro is currently the cheapest entry point into the AI revolution with a P/E of 12, despite doubling its revenue to an incredible $28 billion. While the Malaysian plant is churning out hardware for Meta and Tesla, the US Department of Justice is breathing down the company’s neck over a $2.5 billion export scandal. It’s a classic high-risk, high-reward play: you’re either buying a future titan at a fire-sale price, or boarding a ship that’s already being dismantled by lawyers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.